Sun Pharma and Lupin get tentative USFDA nod for schizophrenia drug

The drug is used to treat certain mental disorders such asschizophrenia, depression associated with bipolar disorder.

Sun Pharma and Lupin Ltd have received tentative approval for Lurasidone Hydrochloride by the US Food and Drug Administration (USFDA). The drug is used to treat certain mental disorders such asschizophrenia, depression associated with bipolar disorder. 

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 817.55, up by Rs. 9.75 or 1.21% from its previous closing of Rs. 807.8 on the BSE. The scrip opened at Rs. 817 and has touched a high and low of Rs. 822.9 and Rs. 815 respectively. So far 944861(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 194410.48 crore.

Lupin Ltd is currently trading at Rs. 1718.25, up by Rs. 19 or 1.12% from its previous closing of Rs. 1699.25 on the BSE. The scrip opened at Rs. 1720 and has touched a high and low of Rs. 1724.75 and Rs. 1708.6 respectively. So far 114619(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 76550.61 crore.